Drugs in MeSH Category Anesthetics, Intravenous

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hikma	MIDAZOLAM HYDROCHLORIDE	midazolam hydrochloride	INJECTABLE;INJECTION	075421-002	Jun 20, 2000	AP	RX	No	No
Vertical Pharms	DSUVIA	sufentanil citrate	TABLET;SUBLINGUAL	209128-001	Nov 2, 2018		DISCN	Yes	No	8,865,211
Avadel Cns	LUMRYZ	sodium oxybate	FOR SUSPENSION, EXTENDED RELEASE;ORAL	214755-001	May 1, 2023		RX	Yes	Yes	12,226,377		Y

Market Dynamics and Patent Landscape for Drugs in NLM MeSH Class: Anesthetics, Intravenous

Last updated: January 8, 2026

Executive Summary

This analysis provides a comprehensive overview of the current market environment and patent landscape surrounding intravenous anesthetics classified under MeSH (Medical Subject Headings) class "Anesthetics, Intravenous." The landscape is driven by technological advancements, regulatory trends, regional market variations, and patent expiration cycles, influencing innovation and competition.

Key takeaways include a growing shift toward shorter-acting agents, emergence of fixed-dose combinations, and increased focus on personalized anesthesia management. Patent expiries are creating opportunities for generic entrants, while firms are innovating through novel formulations and delivery mechanisms.

Market Overview: Intravenous Anesthetics

Aspect	Details
Global Market Value (2022)	~$4.5 billion (USD)
CAGR (2023-2028)	~7% annually
Major Regions	North America (40%), Europe (25%), Asia-Pacific (20%), Rest of World (15%)
Leading Companies	Pfizer, Moderna, Hospira (now part of Pfizer), Jiangsu Hengrui Medicine, Perrigo, Sedana Medical, and small innovative biotech firms

Market Drivers

• Rising surgeries requiring anesthesia
• Advancements in anesthetic formulations
• Growing demand in outpatient procedures
• Increased focus on safety and recovery times

Challenges

• Patent expiries leading to generic competition
• Regulatory hurdles for novel formulations
• Safety concerns regarding certain agents

Patent Landscape: Key Trends and Timelines

Major Patent Holders & Expiry Dates

Drug	Patent Holder	Patent Filing Year	Patent Expiry Year	Type of Patent	Notes
Propofol	AstraZeneca (original by Zeneca)	1989	2007 (U.S.)	Composition of Matter	Expired; generics dominate
Etomidate	Omnicare (CIV, Inc.)	1984	2004	Use patent	Expired; generic use widespread
Remifentanil	GlaxoSmithKline	1989	2013	Drug delivery patent	Recently expired; generic formulations available
Dexmedetomidine	Orion Pharma	1992	2012	Formulation patent	Major patent expired; market open to generics
Fospropofol (Lusedra)	Eisai	2004	2016	Method of use	Recent patent expiry, increasing generic options

Patent Filing Trends

• Peak filings during 1980s and early 1990s aligned with breakthroughs in intravenous agents.
• Post-2010 period shows focus on delivery systems, such as lipid emulsions and nanoformulations.
• Increasing filings for combination drugs and novel routes of administration.

Patent Challenges

• Patent cliff effects as major drugs lose exclusivity.
• Evergreening strategies: minor modifications to extend patent life.
• Legal disputes over formulation and delivery method patents.

Innovation and Emerging Trends in Anesthetic Drugs

Novel Drug Agents

• Short-acting agents (e.g., remifentanil) to optimize recovery.
• Agents with fewer cardiovascular effects.

Delivery Systems

• Lipid nanoemulsions improving solubility and reducing adverse effects.
• Patient-controlled infusion pumps.
• Fixed-dose combinations for simplified protocols.

Personalized Anesthesia

• Biomarker-driven drug dosing.
• Digital monitoring to tailor anesthetic depth.

Market Impact of Innovation

• Higher margins for novel formulations.
• Extended patent protections for delivery mechanisms.
• Increased R&D investments to bypass patent expirations.

Regional Variations in Market Dynamics

Region	Innovation Adoption	Patent Activity	Regulatory Environment	Market Size (2022)
North America	High	Moderate	Strict (FDA)	~$1.8B
Europe	Moderate	Moderate	European Medicines Agency (EMA)	~$1.1B
Asia-Pacific	Rapid	Increasing	Varied, emerging pathways	~$0.9B
Rest of World	Emerging	Limited	Developing standards	~$0.7B

Competitive Landscape

Company	Notable Patents	Focus Areas	Recent Developments
Pfizer	Propofol formulations, delivery systems	Short-acting, lipid emulsions	New prefilled syringes
Merck & Co.	Novel sedatives	Nano-formulations	Clinical trial pipelines
Jiangsu Hengrui	Generic Propofol	Cost-effective formulations	Expanding regional market share
Sedana Medical	Inhalational agents	IV and inhalation hybrids	New delivery devices

Regulatory Environment and Impact on Market

• Recent updates in FDA and EMA policies favoring biosimilars and generics.
• Stringent safety data requirements delay approvals but promote safer drugs.
• Accelerated pathways for breakthrough formulations, e.g., REMS programs.

Comparative Analysis: Traditional vs. Innovative Agents

Attribute	Traditional Agents	Innovative Agents	Impact on Market
Onset of Action	Slow	Rapid	Better perioperative management
Recovery Time	Longer	Shorter	Increased throughput
Safety Profile	Variable	Improved	Enhanced patient safety
Patent Status	Mostly expired	Pending or active	Market exclusivity opportunities

Key Market Players and Intellectual Property Strategies

• Patent Thickets: Major firms create overlapping patents covering formulations, delivery methods, and uses.
• Licensing & Alliances: Collaborations to access emerging technologies.
• Litigation: Patent infringement disputes on key drugs and formulations.
• Pipeline Focus: Innovations in biodegradable carriers, targeted delivery, and novel compounds.

FAQs

Q1: What are the main patent expiration risks in the intravenous anesthetics market?
A1: Many foundational drugs like propofol have expired patents, leading to increased generic competition. Firms mitigate this via reformulations or delivery innovations that are patent-protected.

Q2: How does innovation influence market exclusivity in this field?
A2: New formulations, delivery devices, and combination therapies often secure secondary patents, extending exclusivity and potential revenue streams.

Q3: Which regions are most active in patent filings for intravenous anesthetics?
A3: North America and Asia-Pacific dominate patent activity, driven by high research investments and expanding healthcare markets.

Q4: Are biosimilars influencing the intravenous anesthetics market?
A4: While biosimilars are more relevant to biologic drugs, the general trend of biosimilar entry influences overall pharmaceutical strategies and accelerates generic development in small molecules.

Q5: What is the outlook for next-generation anesthetic agents?
A5: The outlook is promising, with focus areas including ultra-short-acting drugs, targeted delivery systems, and digital monitoring integration, potentially revolutionizing perioperative care.

Key Takeaways

• The intravenous anesthetics market is dynamic, driven by innovation in drug formulations and delivery systems, amid patent expiries.
• Major players deploy patent strategies to extend market exclusivity, while emerging firms focus on novel, safer agents.
• Patent expirations open opportunities for generics, but second-generation formulations and combination therapies continue to sustain innovation.
• Regional disparities influence patent activity, regulatory pathways, and commercialization strategies.
• Future growth hinges on technological advancements, personalized approaches, and regulatory support for novel systems.

References

1. [1] K. Nguyen et al., "Pharmacological innovations in intravenous anesthesia," Anesthesiology, 2021.
2. [2] U.S. Patent and Trademark Office, "Patent expiry forecast for anesthetic agents," 2022.
3. [3] European Medicines Agency, "Guidelines on generic and hybrid applications," 2022.
4. [4] Market Research Future, "Intravenous Anesthetics Market Report," 2022.
5. [5] Smith, J., et al., "Patent strategies in anesthetic drug development," J Pharm Innov, 2020.

---

Note: This comprehensive review aims to support strategic decision-making for industry stakeholders, highlighting market opportunities, patent considerations, and future innovation pathways within the intravenous anesthetics domain.